Baxter International Inc (BAX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Baxter International Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 26.20 $ — 95% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 4.2% above the current price.
- Consensus
- Hold
- Analyst Ratings
- 18
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2.04 | 1.97 – 2.09 | 11,601 | -10.0% | 10 |
| 12/31/2027 | 2.06 | 1.94 – 2.45 | 11,824 | 0.6% | 14 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.00 | -307.80 | 2,753 | -29.10 | -18.60 | 488 | 351 |
| 2025: Q1 | 0.25 | 237.90 | 2,625 | 5.40 | 4.80 | -193 | -315 |
| 2025: Q2 | 0.18 | – | 2,810 | 4.30 | 3.20 | 217 | 68 |
| 2025: Q3 | -0.09 | -132.70 | 2,835 | 5.00 | -1.60 | 237 | 126 |
| 2025: Q4 | -2.19 | – | 2,974 | 8.00 | -37.90 | 584 | 444 |
| 2026: Q1 | -0.03 | -111.90 | 2,701 | 2.90 | -0.60 | 213 | 76 |
| 2026: Q2 | 0.24 | 33.30 | 2,960 | 5.30 | 4.30 | 285 | 285 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 10,163 | 745 | 4,965 | 9.01 | 1,654 | 8,290 | 15,546 |
| 2017 | 10,584 | 1,288 | 602 | 1.08 | 1,714 | 9,124 | 17,111 |
| 2018 | 11,099 | 1,584 | 1,546 | 2.83 | 2,017 | 7,844 | 15,720 |
| 2019 | 11,362 | 1,772 | 1,001 | 1.93 | 2,104 | 7,882 | 18,193 |
| 2020 | 11,673 | 1,616 | 1,102 | 2.13 | 1,868 | 8,689 | 20,019 |
| 2021 | 12,146 | 1,350 | 1,284 | 2.53 | 2,222 | 9,077 | 33,521 |
| 2022 | 10,057 | -2,845 | -2,433 | -4.83 | 1,211 | 5,833 | 28,287 |
| 2023 | 10,360 | 707 | 2,656 | 5.25 | 1,726 | 8,402 | 28,276 |
| 2024 | 10,636 | 14 | -649 | -1.27 | 1,019 | 6,964 | 25,782 |
| 2025 | 11,244 | -308 | -957 | -1.87 | 845 | 6,129 | 20,055 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Baxter International Inc. bietet über ihre Tochtergesellschaften ein Portfolio von Gesundheitsprodukten in den USA an.
| Employees | 37,500 |
|---|---|
| Headquarters | Deerfield, IL |
| Address | One Baxter Parkway, 60015 Deerfield, United States |
| Phone | 224 948 2000 |
| Website | baxter.com |
| IPO Date | 27. Oct 1981 |
| ISIN | US0718131099 |
| Stock Split | 1841:1000 on 07/01/2015 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Andrew P. Hider | CEO, President, Interim Group President of Medical Products & Therapies and Director | 1977 |
| David S. Rosenbloom | Executive VP & General Counsel | 1960 |
| Maria Soriano | Group President of Infusion Therapies & Platforms | – |
| Anita A. Zielinski | Interim CFO, Senior VP, Chief Accounting Officer & Controller | 1973 |
| Charles Rusty Patel | Senior VP & Chief Information Officer | 1970 |
| Kevin Moran | Vice President & Head of Investor Relations | – |
| Stacey Eisen | SVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation | – |
| Cynthia Carlisle | Executive VP & Chief Human Resources Officer | 1976 |
| James W. Borzi | Executive VP & Chief Supply Chain Officer | 1963 |
| Steven P. Wallace | President of Advanced Surgery & Commercial Excellence | 1981 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.